Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Golden Throat Holdings Group Co's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$259 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$332 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Golden Throat Holdings Group Co's annualizedROC % for the quarter that ended in Dec. 2025 was 31.09%.
Golden Throat Holdings Group Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 83.92%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Golden Throat Holdings Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 26.99%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Golden Throat Holdings Group Co EBIT Related Terms
Golden Throat Holdings Group Co EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Golden Throat Holdings Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Golden Throat Holdings Group Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Golden Throat Holdings Group Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Golden Throat Holdings Group Co's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$332 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Golden Throat Holdings Group Co (HKSE:06896) has a EBIT of HK$332 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Golden Throat Holdings Group Co.
Is Golden Throat Holdings Group Co's EBIT too high?
Golden Throat Holdings Group Co's current EBIT is HK$332 Mil. Overall, Golden Throat Holdings Group Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Golden Throat Holdings Group Co's EBIT compare to ZTS?
Golden Throat Holdings Group Co's EBIT of HK$332 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Golden Throat Holdings Group Co. Golden Throat Holdings Group Co's current EBIT is HK$332 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Golden Throat Holdings Group Co stock overvalued right now?
Based on GuruFocus' analysis, Golden Throat Holdings Group Co (HKSE:06896) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$2.98, compared to a current price of HK$2.27 — trading 24% below its estimated fair value. The current EBIT is HK$332 Mil. Golden Throat Holdings Group Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Golden Throat Holdings Group Co (HKSE:06896), the current EBIT is HK$332 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Golden Throat Holdings Group Co (HKSE:06896) Overvalued in 2026?
Based on GuruFocus' analysis, Golden Throat Holdings Group Co stock appears to be undervalued.
The current stock price of HK$2.27 is trading 24% below its estimated GF Value™ of HK$2.98.
GuruFocus considers Golden Throat Holdings Group Co to be Modestly Undervalued.
Key valuation signals for HKSE:06896:
EBIT: HK$332 Mil
GF Value™: HK$2.98 vs. price of HK$2.27 (24% below fair value)
No single metric tells the full story. See the HKSE:06896 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Golden Throat Holdings Group Co Ltd is an investment holding company. Through its subsidiaries, the company is engaged in the manufacture and sale of pharmaceuticals, healthcare food and other products. The compqny manufactures and sells lozenges and other pharmaceutical and food products. The key products of the group that derives revenue for the group are Golden Throat Lozenges (OTC), Golden Throat Lozenge Series products and other products. The group derives majority of its revenue from Mainland China.
83GF Score
Get the complete analysis for HKSE:06896
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06896 has been successfully added to your 
